Market Overview

UPDATE: Jefferies & Company Reiterates Buy Rating, Lowers PT on Pfizer

Related PFE
Encouraging Results from Pfizer's Xeljanz - Analyst Blog
Pharma M&A Frenzy Pushing These ETFs Higher - ETF News And Commentary
Pharma Deal Frenzy: A Bid to Boost Profits, Cut Risk (Fox Business)

In a report published Monday, Jefferies & Company reiterated its Buy rating on Pfizer (NYSE: PFE), but slightly lowered its price target from $28.00 to $27.00.

Jefferies noted, “The 5% revenue miss in Q3'12 was forgiven to a degree as Lipitor phasing was partly to blame and EPS was still delivered through financial engineering. Lighter than expected Prevnar-13 and Enbrel sales were more concerning, though we now have the US launches of tofacitinib and hopefully Eliquis within the next 3-6 months to look forward to. New product launches, share repurchases and restructuring drive near term upside in our view.”

Pfizer closed on Friday at $24.16.

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings

 

Most Popular

Related Articles (PFE)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free